Natixis Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$96.2M Buy
2,006,551
+666,676
+50% +$28.6M 0.11% 177
2026
Q1
$49.2M Sell
1,339,875
-1,321,363
-50% -$62.6M 0.07% 276
2025
Q4
$135M Buy
2,661,238
+105,703
+4% +$5.41M 0.19% 118
2025
Q3
$142M Sell
2,555,535
-277,536
-10% -$16.2M 0.21% 108
2025
Q2
$196M Sell
2,833,071
-81,033
-3% -$5.51M 0.31% 62
2025
Q1
$202M Sell
2,914,104
-109,909
-4% -$9.08M 0.37% 51
2024
Q4
$260M Sell
3,024,013
-50,863
-2% -$5.5M 0.49% 34
2024
Q3
$366M Buy
3,074,876
+80,070
+3% +$10.7M 0.71% 19
2024
Q2
$427M Buy
2,994,806
+846
+0% +$112K 0.93% 12
2024
Q1
$384M Sell
2,993,960
-58,446
-2% -$6.96M 0.88% 13
2023
Q4
$316M Buy
3,052,406
+55,333
+2% +$5.47M 0.83% 13
2023
Q3
$273M Sell
2,997,073
-58,095
-2% -$5.12M 0.83% 12
2023
Q2
$247M Buy
3,055,168
+43,960
+1% +$3.59M 0.76% 16
2023
Q1
$240M Buy
3,011,208
+94,554
+3% +$6.7M 0.82% 11
2022
Q4
$197M Sell
2,916,654
-51,186
-2% -$3M 0.75% 11
2022
Q3
$148M Buy
2,967,840
+150,996
+5% +$8.09M 0.63% 18
2022
Q2
$157M Buy
2,816,844
+405,290
+17% +$22.5M 0.69% 14
2022
Q1
$134M Buy
2,411,554
+381,426
+19% +$19.6M 0.51% 32
2021
Q4
$114M Sell
2,030,128
-549,576
-21% -$29.8M 0.43% 47
2021
Q3
$124M Buy
2,579,704
+627,170
+32% +$30.3M 0.51% 35
2021
Q2
$81.8M Sell
1,952,534
-36,512
-2% -$1.42M 0.38% 49
2021
Q1
$67M Buy
1,989,046
+130,660
+7% +$4.65M 0.35% 55
2020
Q4
$64.9M Sell
1,858,386
-240,692
-11% -$8.32M 0.37% 53
2020
Q3
$72.9M Sell
2,099,078
-48,916
-2% -$1.63M 0.46% 43
2020
Q2
$70.3M Sell
2,147,994
-879,250
-29% -$28.1M 0.47% 38
2020
Q1
$91.1M Sell
3,027,244
-397,692
-12% -$11.8M 0.74% 22
2019
Q4
$99.1M Sell
3,424,936
-135,408
-4% -$3.75M 0.7% 21
2019
Q3
$92M Sell
3,560,344
-136,658
-4% -$3.46M 0.73% 20
2019
Q2
$94.3M Buy
3,697,002
+10,974
+0.3% +$271K 0.77% 17
2019
Q1
$96.4M Buy
3,686,028
+121,604
+3% +$2.99M 0.84% 14
2018
Q4
$82.1M Buy
3,564,424
+3,704
+0.1% +$82.3K 0.81% 21
2018
Q3
$83.9M Buy
3,560,720
+499,644
+16% +$12.2M 0.74% 18
2018
Q2
$70.6M Sell
3,061,076
-415,640
-12% -$9.88M 0.67% 19
2018
Q1
$85.6M Sell
3,476,716
-50,108
-1% -$1.32M 0.85% 16
2017
Q4
$94.6M Buy
3,526,824
+106,376
+3% +$2.71M 0.96% 12
2017
Q3
$82.3M Buy
3,420,448
+328,742
+11% +$7.43M 0.87% 16
2017
Q2
$66.3M Buy
3,091,706
+89,896
+3% +$1.81M 0.72% 20
2017
Q1
$51.5M Buy
3,001,810
+631,046
+27% +$11M 0.57% 31
2016
Q4
$42.5M Buy
2,370,764
+364,288
+18% +$6.6M 0.51% 37
2016
Q3
$41.7M Buy
2,006,476
+200,582
+11% +$4.97M 0.54% 36
2016
Q2
$48.6M Buy
1,805,894
+36,378
+2% +$998K 0.67% 27
2016
Q1
$47.9M Buy
1,769,516
+123,946
+8% +$3.32M 0.72% 22
2015
Q4
$47.8M Buy
1,645,570
+13,134
+0.8% +$364K 0.78% 16
2015
Q3
$44.3M Buy
1,632,436
+221,204
+16% +$6.26M 0.77% 19
2015
Q2
$38.6M Buy
1,411,232
+169,712
+14% +$4.77M 0.66% 19
2015
Q1
$33.1M Buy
1,241,520
+274,742
+28% +$6.33M 0.58% 20
2014
Q4
$20.5M Buy
966,778
+244,032
+34% +$5.45M 0.38% 37
2014
Q3
$17.2M Sell
722,746
-456,006
-39% -$10.5M 0.35% 41
2014
Q2
$27.2M Buy
1,178,752
+74,736
+7% +$1.65M 0.39% 27
2014
Q1
$25.2M Buy
1,104,016
+696,886
+171% +$14.8M 0.39% 30
2013
Q4
$1.5M Sell
407,130
-22,430
-5% -$391K 0.02% 645
2013
Q3
$7.27M Buy
429,560
+11,700
+3% +$197K 0.13% 258
2013
Q2
$6.47M Buy
+417,860
New +$6.95M 0.13% 276

Other funds holding NVO

Natixis Advisors's NVO Position: Q2 2026 in Review

Natixis Advisors increased its Novo Nordisk (NVO) stake by 50% in Q2 2026, buying an estimated $28.6M and bringing the position to 2,006,551 shares worth $96.2M. The position accounts for 0.11% of the portfolio, ranked #177.

Natixis Advisors first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $427M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Natixis Advisors held 2,006,551 shares of Novo Nordisk worth $96.2M as of Q2 2026.
  • Natixis Advisors bought 666,676 Novo Nordisk shares in Q2 2026, an estimated $28.6M.
  • Novo Nordisk made up 0.11% of Natixis Advisors's portfolio in Q2 2026, its #177 holding.
  • Natixis Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Natixis Advisors's Novo Nordisk position peaked at $427M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.